# Safety Study of Low Dose Interleukin 2 (IL-2) Plus PEG-IFN/RBV In Chronic Hepatitis C Virus Genotype I

> **NCT00277758** · PHASE1 · TERMINATED · sponsor: **Weill Medical College of Cornell University** · enrollment: 18 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **BIOLOGICAL:** Interleukin 2
- **DRUG:** Ribavirin
- **BIOLOGICAL:** Pegylated Interferon Alpha
- **BIOLOGICAL:** Inteleukin-2
- **DRUG:** Ribavirin + Pegylated interferon-alpha

## Key facts

- **NCT ID:** NCT00277758
- **Lead sponsor:** Weill Medical College of Cornell University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-03
- **Primary completion:** 2006-07
- **Final completion:** 2006-08
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** Insufficient rate of volunteer accrual.
- **Last updated:** 2008-03-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00277758

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00277758, "Safety Study of Low Dose Interleukin 2 (IL-2) Plus PEG-IFN/RBV In Chronic Hepatitis C Virus Genotype I". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00277758. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*